I-3-Aminopiperidine-2,6-Dione Hydrochloride CAS 24666-56-6;2686-86-4 Ubunyulu > 99.0% iLenalidomide Intermediate Factory
I-Ruifu Chemical ngumenzi ohamba phambili we-3-Aminopiperidine-2,6-Dione Hydrochloride (CAS: 24666-56-6; 2686-86-4) enomgangatho ophezulu, ophakathi kwePomalidomide (CAS: 19171-19-8).I-Ruifu Chemical inokubonelela ngenkonzo yehlabathi jikelele, ixabiso elikhuphisanayo, inkonzo egqwesileyo, encinci kunye nezixa ezininzi ezikhoyo.Thenga i-3-Aminopiperidine-2,6-Dione Hydrochloride, Please contact: alvin@ruifuchem.com
| Igama leMchiza | I-3-Aminopiperidine-2,6-Dione Hydrochloride |
| Izithethantonye | I-3-Aminopiperidine-2,6-Dione HCl;3-Amino-2,6-Piperidinedione Hydrochloride;2,6-Dioxopiperidine-3-Ammonium Chloride |
| Inombolo yeCAS | 24666-56-6 |
| CAS ezinxulumene | 2686-86-4;25181-50-4 |
| Ubume beStokhwe | Kwi-Stock, iMveliso yoMveliso ukuya kwiiToni |
| Ifomula yeemolekyuli | I-C5H9ClN2O2 |
| Ubunzima beMolekyuli | 164.59 |
| Indawo yokunyibilika | 120℃ |
| I-COA kunye ne-MSDS | Iyafumaneka |
| Imvelaphi | Shanghai, China |
| Uphawu | Ruifu Chemical |
| Into | Iinkcukacha |
| Imbonakalo | Umgubo weCrystalline oMhlophe |
| Ubunyulu / Indlela yokuHlalutya | >99.0% (HPLC) |
| Ukufuma (KF) | <0.50% |
| Ilahleko ekomisweni | <0.50% |
| Intsalela kwi-Ignition | <0.20% |
| Ukungcola ngokupheleleyo | <1.00% |
| I-Infrared Spectrum | Iyahambelana noLwakhiwo |
| Umgangatho woVavanyo | Umgangatho woShishino |
| Ukusetyenziswa | Umbindi weLenalidomide (CAS: 191732-72-6) |
Iphakheji: Ibhotile, ingxowa yefoyile yeAluminiyam, 25kg/Igubu lekhadibhodi, okanye ngokwemfuno yomthengi
Imeko yoGcino:Gcina kwizikhongozeli ezivaliweyo kwindawo epholileyo neyomileyo;Khusela ukukhanya kunye nokufuma
I-3-Aminopiperidine-2,6-Dione Hydrochloride (CAS: 24666-56-6; 2686-86-4) iphakathi ukulungiselela iLenalidomide (CAS: 191732-72-6).ILenalidomide luhlobo lwamachiza e-antitumor aphuhliswe ziinkampani zaseMelika zebhayoloji ezixuba amayeza.Inemisebenzi emininzi efana ne-anti-tumor, i-immune regulation kunye ne-anti-angiogenesis.Inokuthintela ukukhuselwa kwee-cytokines ezivuthayo, kunye nokwandisa imfihlo ye-peripheral blood mononuclear anti-inflammatory cytokines.Inokuthintela ukukhula kweeseli ze-myeloma ezininzi zezigulane kunye neseli ye-MM1S.Izifundo ezimbini zeklinikhi ezilawulwa ngokungenamkhethe eziphindwe kabini ze-placebo zivavanya ukhuseleko kunye nesiphumo sonyango se-lenalidomide esetyenziselwa i-myeloma eninzi.Iziphumo zophando lweklinikhi zakutsha nje zibonisa ukuba i-lenalidomide ayinayo kuphela impembelelo yonyango ekunyangeni i-MDS kunye ne-MM, kodwa nakwi-myeloma, i-leukemia, i-metastatic renal cell carcinoma, i-tumor eqinile, i-idiopathic generalized amyloidosis kunye ne-systemic bone marrow fibrosis isifo esinomongo ongavuthwanga.NgoDisemba 2005, i-US Food and Drug Administration (FDA) ivume i-lenalidomide ukuba isetyenziswe kunyango lwe-myelodysplastic syndrome (MDS).
